Trice Medical's Mi-Eye Featured in Businessweek

Trice Medical's Mi-Eye Featured in Businessweek

Bloomberg Businessweek columnist Michael Belfiore featured Trice's Mi-Eye device as a key innovation to watch (see here: https://www.bloomberg.com/news/articles/2017-02-16/this-needle-cam-can-diagnose-joint-injuries-without-an-mri ). The Mi-Eye allows doctor's to immediately diagnose knee injuries by direct visualization via an "optical needle", thereby eliminating the trip to the MRI.

Vestagen protects Healthcare workers in NYC with Northwell Health

Vestagen protects Healthcare workers in NYC with Northwell Health

Vestagen Protective Technologies has begun supplying uniforms to Northwell Health, the largest hospital system in New York, with 60,000 healthcare workers. News outlets in New York City have given great coverage, including this from NY1 TV: http://www.ny1.com/nyc/all-boroughs/health-and-medicine/2017/02/22/germ-resistant-scrubs-gaining-traction-in-city-hospitals.html

HealthQuest Leads Investment in Avizia

HealthQuest Leads Investment in Avizia

Avizia, the leading end to end telehealth solution provider, today announced the completion of its Series A financing totaling $17 million. The company raised an additional $6 million to supplement the initial $11 million, which was announced in July 2016. HealthQuest Capital led the additional round which included investment from strategic partner NewYork-Presbyterian. 

Trice Medical Receives FDA Clearance for MiEye2

Trice Medical Receives FDA Clearance for MiEye2

Trice Medical announced today that it received 510(k) clearance from the U.S. Food and Drug Administration ("FDA") for mi-eye 2, a disposable needle with a fully integrated camera that enables physicians to use advanced diagnostic imaging to visualize joint injuries in their clinic. 

HealthQuest leads $13.8M into Magnolia Medical

HealthQuest leads $13.8M into Magnolia Medical

Magnolia Medical Technologies, developer of the SteriPath® blood collection system and leader in improving the quality and accuracy of in-vitro diagnostic test results, today announced the closing of the company's $13.8 million Series B financing led by HealthQuest Capital. In conjunction with the financing, Garheng Kong, M.D., Ph.D., founder and managing partner of HealthQuest Capital will join the company's board.

Virmedica Expands Senior Management Team

Virmedica Expands Senior Management Team

VirMedica, the leader in providing e-access and specialty pharmacy technology solutions designed to expedite patient access to biopharmaceutical products, today announced the appointment of three new executives to the Company's senior leadership team. John J. Arcari has been appointed to chief financial officer (CFO) and will oversee the Company's financial operations. Richard Deyermond joins the company as vice president of client services and will lead teams engaged in the delivery of VirMedica's technology solutions. As the vice president of engineering, Elizabeth Ricci will focus on building out the Company's technology suite.

Virmedica Appoints Phil Lee as CEO

Virmedica Appoints Phil Lee as CEO

VirMedica, the leader in providing eACCESS technology solutions designed to expedite patient access to biopharmaceutical products, today announced that its Board of Directors has appointed Philip Lee as president, chief executive officer (CEO) and a member of the Board of Directors, effective immediately.

William A. Hawkins III Joins Trice Medical's Board of Directors

William A. Hawkins III Joins Trice Medical's Board of Directors

Trice Medical, an early stage medical device company, announced the appointment of William Hawkins to the company's board of directors, effective April 1, 2016. Hawkins joins a distinguished Board of proven industry leaders in their pursuit to revolutionize arthroscopic diagnostics. Mr. Hawkins is a renowned healthcare executive with diverse experience in healthcare delivery, innovation, and entrepreneurship.

HealthQuest Capital Closes Oversubscribed Fund at $225 Million

HealthQuest Capital Closes Oversubscribed Fund at $225 Million

HealthQuest Capital announced the closing of HealthQuest Capital II, LP, at the hard cap of $225 million and in excess of the initial fund target of $175 million. Investors in the fund include endowments, family offices, foundations, fund-of-funds, pension funds, and global healthcare organizations.

Read More

Spirox Inc. Raises Series C with HealthQuest and KKR

Spirox Inc. Raises Series C with HealthQuest and KKR

Spirox Inc., a privately held medical device company, announced today the closing of a $45 million Series C round of financing led by KKR, a leading global investment firm. Also participating in the financing is new investor HealthQuest Capital along with major existing shareholders Aisling Capital, Aperture Venture Partners and Venrock.

Read More

Vestagen raises $7M, appoints new CEO.

Vestagen raises $7M, appoints new CEO.

Orlando, Florida-based Vestagen Technical Textiles Inc, a medical technology company developing apparel for healthcare applications, raised $7 million in financing. Advent Life Sciences and HealthQuest Capital led the round, which was a planned extension of the company’s previous financing. Vestagen also named Bill Bold as chief executive officer. Bold replaces Dale Pfost, PhD, who was serving as interim CEO and remains chairman of the board.

Read More

 BioTheranostics Raises $32M from HealthQuest and Others

BioTheranostics Raises $32M from HealthQuest and Others

BioTheranostics, a leader in molecular diagnostics for cancer, today announced that it has closed a $32 million financing led by MVM Life Science Partners, with participation of Canepa Advanced Healthcare Fund and HealthQuest Capital. As a result of the financing, bioTheranostics will be spun out from bioMérieux, which will remain a minority shareholder, and operate as an independent company.

Read More

Castle Biosciences Presents Data on Unique Genetic Test for Predicting Cancer Recurrence in Soft Tissue Sarcoma

Castle Biosciences Presents Data on Unique Genetic Test for Predicting Cancer Recurrence in Soft Tissue Sarcoma

Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the presentation of data from a new test discovered by the Company to assess the risk of cancer recurrence in patients diagnosed with soft tissue sarcomas (STS). Results were presented in a poster session at the Connective Tissue Oncology Society Annual Meeting, November 4-7, 2015 in Salt Lake City.

Read More

Castle Biosciences appoints new Chief Medical Officer

Castle Biosciences appoints new Chief Medical Officer

Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the appointment of Federico A. Monzon, M.D. FCAP, to the newly created role of Chief Medical Officer.  The Company also announced the appointment of Greg Schafer to Executive Director of Managed Care.

Read More

HealthQuest invests in Inmediata

HealthQuest invests in Inmediata

inMediata, a healthcare payments and EDI company, is committed to solving payment problems for stakeholders in the healthcare industry.

When it comes to the healthcare reimbursement process, inMediata takes a different approach. The company is committed to solving payment problems for customers, and has built innovative healthcare technology solutions by listening and responding to the needs of their customers.

Read More →

More New Hospitals and Nursing Schools Convert Apparel to Vestex

More New Hospitals and Nursing Schools Convert Apparel to Vestex

Adoption of innovative fabric technology for healthcare worker and patient attire is growing, as more healthcare facilities forego traditional uniforms in an effort to better protect patients and staff from healthcare-associated infections (HAIs). As one indicator of this growth, Vestagen Technical Textiles reports that a variety of healthcare facilities have recently converted to its VESTEX protective uniforms.

Read More

Castle Biosciences receives payer coverage decisions covering 120 million lives

Castle Biosciences receives payer coverage decisions covering 120 million lives

Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the Company has secured payer contracts with national provider networks MultiPlan, Inc., FedMed, Inc. and Preferred Medical Claim Solutions, LLC to provide coverage of its DecisionDx assays. These networks together provide access to more than 120 million covered lives.

Read More →

Vestex from Vestagen receives exclusive endorsement from American Hospital Assn

Vestex from Vestagen receives exclusive endorsement from American Hospital Assn

The American Hospital Association (AHA) today announced it has exclusively endorsed Vestagen Technical Textiles, Inc.’s Vestex® Active Barrier Apparel, a protective fabric that combines fluid repellency and antimicrobial technologies embedded into health care worker scrubs, lab coats and jackets. AHA Solutions, Inc., a subsidiary of the AHA, awards the AHA Endorsement to products and services that help member hospitals and health care organizations achieve operational excellence.

Read More